| Generic name | Isatuximab-irfc |
| Brand name(s), other common name(s) |
Sarclisa® |
| Drug type | CD38-directed cytolytic antibody (monoclonal antibody) |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Isatuximab-irfc is FDA approved
- In combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
- In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
Side effects needing medical attention
The most common adverse reactions were neutropenia, infusion-related reactions, pneumonia, upper respiratory tract infection, and diarrhea. The most common hematology laboratory abnormalities were anemia, neutropenia, abnormally low level of lymphocytes in the blood (lymphopenia), and thrombocytopenia.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.